Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Allena Pharmaceuticals's Enterprise Value is $0.00 Mil.
Allena Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $-42.41 Mil. Therefore, Allena Pharmaceuticals's EV-to-EBIT ratio for today is 0.00.
Allena Pharmaceuticals Enterprise Value Historical Data
The historical data trend for Allena Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allena Pharmaceuticals's Enterprise Value
For the Biotechnology subindustry, Allena Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allena Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's Enterprise Value falls into.
Allena Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Allena Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals (OTCPK:ALNAQ) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Allena Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Allena Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.41 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Allena Pharmaceuticals's EV-to-EBITDA for today is:
Allena Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Allena Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.95 Mil.
Allena Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Allena Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Allena Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNAQ has been successfully added to your 